Wandara is indicated for the treatment of moderate to severe infections caused by susceptible strains of microorganisms. It is also used for initial empiric therapy before identifying causative organisms in the following infections:
Additionally, Wandara is indicated for the prophylaxis of surgical site infections following elective colorectal surgery in adults.
Note: Always take this medication according to the advice of a registered healthcare professional.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
It is not recommended to use alcohol with Wandara 1gm Injection. Please consult your doctor if you have any concerns.
Wandara 1gm Injection is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
Wandara 1gm Injection is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Monitoring of the infants for any undesired effects like diarrhea or thrush is necessary if this medicine is used in breastfeeding women.
Wandara 1gm Injection may cause side effects which could affect your ability to drive. Certain side effects, such as dizziness and sleepiness, have been reported with Alerta Injection, which may affect some patients’ ability to drive or operate machinery
Wandara 1gm Injection should be used with caution in patients with a known history of renal impairment due to the increased risk of severe side effects. Appropriate dose adjustments should be considered based on the clinical condition.
Exercise caution before using Wandara 1gm Injection in case of an established Liver Patient Please consult your doctor to address any concerns.
Ertapenem works by killing the bacteria that cause infections. It binds to the bacterial cell wall and disrupts the bacterial cell wall synthesis which causes the death of susceptible microorganisms. As a result, it prevents the growth and spreading of the bacteria which therefore controls the severity of the infection.
Most adverse effects reported in clinical studies are mild to moderate. Common drug-related side effects include:
Uncommon side effects may include:
Preparation for Intravenous Administration:
Preparation for Intramuscular Administration:
Visual Inspection: Inspect the parenteral drug visually for particulate matter and discoloration before use. Solutions of Ertapenem may range from colorless to pale yellow; variations within this range do not affect potency.
Note: Always adhere to a registered healthcare professional’s advice when using this medication.
Ertapenem is the active ingredient in Wandara and is a sterile, synthetic, long-acting parenteral 1-β methyl-carbapenem. It is structurally related to beta-lactam antibiotics like penicillins and cephalosporins, exhibiting activity against a broad range of Gram-positive and Gram-negative aerobic and anaerobic bacteria.
Ertapenem acts bactericidal by binding to and inhibiting bacterial penicillin-binding proteins (PBPs). In Escherichia coli, it shows strong affinity for PBPs 1a, 1b, 2, 3, 4, and 5, particularly PBPs 2 and 3. By binding to these proteins, ertapenem disrupts bacterial cell wall synthesis, ultimately inhibiting cell wall formation.
Ertapenem can be administered via IV infusion or IM injection. For intravenous administration, it should be infused over 30 minutes.
For prophylaxis in adults undergoing elective colorectal surgery, the recommended dosage is 1 g IV administered as a single dose 1 hour before the surgical incision.
Renal Impairment:
Hemodialysis: If Ertapenem is given at least 6 hours before hemodialysis, no supplementary dose is required. If given within 6 hours of hemodialysis, a supplementary 30% dose is recommended.
Hepatic Impairment: No dosage adjustment is necessary for patients with impaired hepatic function.
Note: Always follow your doctor's advice regarding medication use.
No specific information is available regarding the treatment of Wandara overdose. However, intravenous administration of Wandara at a 3 g daily dose for 8 days in healthy volunteers did not result in significant toxicity. In pediatric studies, a single IV dose of 40 mg/kg (up to a maximum of 2 g) did not lead to toxicity.
In case of an overdose, discontinue Wandara and provide general supportive treatment until renal elimination occurs. Wandara can be removed by hemodialysis, but specific information regarding the use of hemodialysis for overdose management is lacking.
When Wandara is administered alongside probenecid, it competes for active tubular secretion, leading to increased elimination half-life and systemic exposure. No dosage adjustment is required with probenecid; however, using probenecid to extend Wandara's half-life is not recommended.
Additionally, decreased serum levels of valproic acid have been reported when co-administered with Wandara, so monitoring serum levels of valproic acid is advisable.
Ertapenem is contraindicated in individuals with known hypersensitivity to any components of this product or other drugs in the same class. It is also contraindicated in patients with anaphylactic reactions to beta-lactams and those with known hypersensitivity to local anesthetics of the amide type, severe shock, or heart block.
Ertapenem is classified as pregnancy category B by the FDA. Due to limited studies in pregnant women, it should only be used during pregnancy if the potential benefits justify the potential risks to both mother and fetus. Ertapenem is excreted in human milk, so caution is advised when administering this medication to nursing women.
Before starting therapy with Wandara, inquire about previous hypersensitivity reactions to penicillins, cephalosporins, or other beta-lactams. Discontinue Wandara immediately if any allergic reaction occurs, and provide emergency treatment for serious anaphylactic reactions.
Prolonged use of Wandara may lead to the overgrowth of non-susceptible organisms, requiring repeated evaluations of the patient's condition. If a superinfection occurs, appropriate measures should be taken.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including Wandara. It is important to consider this diagnosis in patients who develop diarrhea after starting antibiotic treatment, as a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated colitis."
For injection: Store at 2-8°C. Keep away from light and out of reach of children. For auxiliary packaging, do not store above 30°C.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.